Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Q1 2025 net product revenue for ZORYVE ® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible ...

Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) ...

Novo Nordisk has pulled ahead in the race to bring the first oral GLP-1 for obesity to market. The company announced Friday ...

The Board of Directors of TRF Limited, at its meeting held today have approved the financial results of the company for the ...

The Board of Directors of Wardwizard Innovations and Mobility Limited, at its meeting held today have approved the financial ...

The FDA pushed back its decision date on Cytokinetics’ heart drug. Elsewhere, Repare Therapeutics licensed its drug discovery ...

This report explores the top FTSE 100 shares to watch next week. The top names include the likes of IAG, IHG, and Flutter ...

Recommendation based on AMPLIFY Phase III trial which showed Calquencecombinations demonstrated statistically significant and clinically meaningfulimprovement in progression-free survival vs.

We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a ...

Discover AstraZeneca's Q1 2025 performance with 10% revenue growth, innovative medicines, and bold 2030 goals.

Below we take a look at what went wrong for BP last quarter. There was more bad news for BP, as it continues to see its woes ...